AstraZeneca has entered into an agreement to acquire Arrow Therapeutics Ltd., a UK biotechnology company focused on the discovery and development of anti-viral therapies, for $150 million in cash. The transaction is expected to close early this year. The acquisition is part of the company’s strategic plan to strengthen its portfolio of anti-infective treatments from external opportunities that complement its internal capabilities in anti-bacterials. The company had previously announce...